Core Cap Advisors, LLC Protagonist Therapeutics, Inc Transaction History
Core Cap Advisors, LLC
- $2.12 Billion
- Q4 2024
A detailed history of Core Cap Advisors, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Core Cap Advisors, LLC holds 76 shares of PTGX stock, worth $2,938. This represents 0.0% of its overall portfolio holdings.
Number of Shares
76
Previous 324
76.54%
Holding current value
$2,938
Previous $14,000
85.71%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
189KPut Options Held
191K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$229 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$223 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$213 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$163 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$129 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.9B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...